-transparent.png){kind=logo}
Malignant pleural mesothelioma (MPM) is an uncommon and usually fatal primary neoplasm of the pleura. In the past, response to standard therapy has been poor [1-3], but recent studies suggest that some patients may benefit from various therapeutic options, including surgical resection, combined technique treatment, and immunotherapy [4-7]. With improvements in therapy, an accurate, widely accepted staging system will be important in selecting homogeneous groups of patients for entry into clinical trials. Multiple staging systems have previously been proposed for MPM, but none are universally used [8].
Related Publications
E F Patz, and
V W Rusch, and
R Heelan
October 1995,
Chest,
E F Patz, and
V W Rusch, and
R Heelan
February 1996,
Lung cancer (Amsterdam, Netherlands),
E F Patz, and
V W Rusch, and
R Heelan
October 1995,
Chest,
E F Patz, and
V W Rusch, and
R Heelan
January 2014,
Acta chirurgica Belgica,
E F Patz, and
V W Rusch, and
R Heelan
March 1995,
Lung cancer (Amsterdam, Netherlands),
E F Patz, and
V W Rusch, and
R Heelan
May 2004,
Cancer imaging : the official publication of the International Cancer Imaging Society,
E F Patz, and
V W Rusch, and
R Heelan
October 2018,
Translational lung cancer research,
E F Patz, and
V W Rusch, and
R Heelan
July 2005,
Lung cancer (Amsterdam, Netherlands),
E F Patz, and
V W Rusch, and
R Heelan
November 2020,
Thoracic surgery clinics,
E F Patz, and
V W Rusch, and
R Heelan
October 2014,
Radiographics : a review publication of the Radiological Society of North America, Inc,
